Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.

Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.

Abstract: A system and method for relief of negative lung pressure during acute laryngospasm or upper airway obstruction, providing a non-toxic gas cartridge capable of supplying between 0.5-5 liters of gas during a procedure, a valve adapted to commence and stop gas release, and a trans-cricothyroid cartilage inflation needle for acutely relieving the negative pressure in the chest. The needle may also be used to insert a guidewire to assist in endotracheal tube insertion.

Abstract: Provided herein is a thermoplastic elastomer hydrogel and methods of making such. The hydrogel comprises a glass formed from poly(styrene)-b-poly(ethylene oxide) in which the coronal chain end has been functionalized with photodimerizable groups (AB-photo) and a liquid medium at a concentration between about 32:1 and about 2:1 liquid medium/AB-photo by weight. The hydrogel has a fatigue resistance to at least 500,000 compression cycles.

Abstract: The present invention relates to an operation control system for spirally operating a capsule endoscope along a tubular organ, and a capsule type endoscope system comprising the same. The operation control system for a capsule endoscope of the present invention comprises: a magnetic field generation portion (100) comprising a first coil unit (110) provided on three orthogonal axes to generate a magnetic field and a second coil unit (120) comprising one coil structure for generating a magnetic field gradient; and a mechanical coil driving portion (130) for three-dimensionally rotating the second coil unit (120), thereby generating a rotating magnetic field and the magnetic field gradient. Therefore, it is possible to simplify the operation control system for a capsule endoscope by forming the rotating magnetic field and the magnetic field gradient for a spiral motion of a capsule endoscope only with a minimum coil system.

Abstract: The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin.

Abstract: The present disclosure relates to a method of doping a 2-dimensional semiconductor. The method of doping a 2-dimensional semiconductor includes: forming an insulating layer including photosensitive particles on a substrate; moving the photosensitive particles included in the insulating layer to a surface of the insulating layer through a heat treatment; forming a 2-dimensional semiconductor layer on the insulating layer; and doping a 2-dimensional semiconductor material included in the 2-dimensional semiconductor layer by exposing the 2-dimensional semiconductor material to a light corresponding to an absorption wavelength of the photosensitive particles included in the insulating layer.

Abstract: Provided herein are all-inorganic perovskite-based films, devices including all-inorganic perovskite-based films, and methods of forming all-inorganic perovskite-based films. The methods may include casting a precursor formulation that includes an all-inorganic perovskite, a liquid, and a polymer. The amount of polymer in the precursor formulation may be less than the amount of all-inorganic perovskite in the precursor formulation.

Abstract: Disclosed herein are a positive electrode active material including at least one selected from among compounds represented by Formula 1 below and a lithium secondary battery including the same that is capable of improving lifetime characteristics and rate characteristics while exhibiting excellent safety: xLi2MyMn(1-y)O3-zAz*(1?x)LiM?O2-z?A?z? (1), where M is at least one element selected from a group consisting of Ru, Mo, Nb, Te, Re, Ir, Pt, Cr, S, W, Os, and Po, M? is at least one element selected from a group consisting of Ni, Ti, Co, Al, Mn, Fe, Mg, B, Cr, Zr, Zn, and second row transition metals, A and A? are each independently a negative monovalent or divalent anion, and 0<x<1, 0.3<y<1, 0?z<0.5, and 0?z?<0.5.

Abstract: The present disclosure relates to compositions and methodology for revealing binding sites between proteins, proteins and nucleic acids, or proteins and small molecules. The disclosure provides rapid and direct positive identification and sequencing of the contact region between such molecules, and can be applied to individual interacting pairs, as well as large-scale or global interactions.

Abstract: A semiconductor photonic device includes a substrate, facet(s), and optical coupler(s) associated with the facet(s). Each optical coupler can couple an electromagnetic field incident on the respective facet towards a buried waveguide as the electromagnetic field proceeds into the semiconductor photonic device. In some examples, each coupler has waveguides extending in a longitudinal direction and at least partly encapsulated within a cladding layer. In some examples, at least one waveguide tapers along its length. In some examples, at least one waveguide includes spaced-apart segments arranged to form a subwavelength grating (SWG) configured to entrain electromagnetic radiation.

Abstract: Systems and methods which generate a sequence of images using turbo spin echo magnetic resonance imaging which are retrospectively correlated with periodic motion occurring within a subject being imaged are described. In one embodiment, k-space measurements (or the measurements from which images are formed) are captured during, and correlated with, different phases in a cardiac cycle of the subject. With this sequence, the images that are produced are able to show, and/or compensate for, motion correlated with the cardiac cycle of the subject.

Abstract: Disclosed is a method for an electronic device. The method may include: acquiring a galvanic skin response; generating a first parameter for a first interval and a second parameter for a second interval based on the galvanic skin response, the second interval being an interval before the first interval; determining a first threshold corresponding to the first interval based on the second parameter; and determining an activity state of the first interval based on the first threshold and the first parameter corresponding to the first interval.

Abstract: A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed.

Abstract: A system for detecting clandestine materials employs a lightweight neutron-source that can be mounted to a remotely controlled mobile platform for flexible and high standoff scanning of possibly explosive materials. In one embodiment, aerial drones hold the neutron-source and detectors for highly flexible remote scanning.

Abstract: Provided are nanocomposites including an iron-based core and a nitrogen-doped graphitic carbon shell, and methods of making and using the same. Included in the nanocomposites is an Fe3C-based interlayer between the core and the shell. The nanocomposites can show a catalytic activity toward reducing oxygen comparable to commercial Pt/C catalysts.

Abstract: Various structures and methods are disclosed related to a computer system for delivering data for operational intelligence in support of optimizing health care delivery. Particular embodiments selectively extract various data sets for operational support from a large electronic medical record (“EMR”) system on schedules of varying frequency to efficiently refresh data during the operational day. Other embodiments enhance EMR extract data using other computerized data sources and/or computer analysis of the EMR data. Other embodiments provide efficient data delivery for operational intelligence to optimize integrated, team-based health care delivery as well virtual medicine and transitional care. These and other embodiments are further disclosed herein.

Abstract: A source node includes a topology information extractor configured to acquire information of a channel state between nodes included in a multicast network, and extract topology information of the multicast network. The source node further includes a relay node selector configured to select, from the nodes, a relay node to relay a packet transmitted from the source node, based on the topology information.

Abstract: Methods for diagnosing and characterizing lymphoma, as well as evaluating the disease-free interval following treatment, utilizing patient antibodies bound to peptide microarrays in comparison to an immunosignature characteristic of a lymphoma state or a non-lymphoma state. Characterization includes subtyping of lymphoma utilizing an immunosignature characteristic of a B-cell or T-cell lymphoma.

Abstract: A method of enhancing therapeutic/drug transport to the perivascular space of the brain of a patient is disclosed. In one embodiment, the method comprises the step of introducing a therapeutic/drug and an osmolyte of the present invention into a patient's cerebrospinal fluid (CSF), wherein the osmolyte is introduced to the CSF at a concentration of between 0.5 and 12.9 M (dependent on the solubility upper limit of the osmolyte), and wherein the therapeutic/drug delivery to the perivascular spaces of cerebral blood vessels and parenchyma of the central nervous system is facilitated by the presence of the osmolyte.